Opendata, web and dolomites

AllergyVAX SIGNED

Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AllergyVAX project word cloud

Explore the words cloud of the AllergyVAX project. It provides you a very rough idea of what is the project "AllergyVAX" about.

relief    patients    modifications    injections    immunological    ait    causes    takes    allergy    basis    pollen    bet    fold    modified    shorten    daily    missed    people    rbet    mice    few    tolerance    economic    global    dozens    release    allergens    allergic    shown    tablets    dm    pipeline    billion    platform    disease    candidates    allergyvax    human    modifying    social    hypoallergen    preclinical    managed    rhinitis    allergies    serious    immunogenicity    peanut    transition    asthma    building    advancing    created    symptoms    training    efficacy    trigger    reactions    dose    million    months    avoiding    tolerate    immune    clinically    proteins    horse    relatively    burden    seamless    allergen    iia    reduce    dog    risk    drugs    trial    treatment    compromising    monthly    symptom    usually    establishing    natural    birch    desired    grass    small    drops    hypoallergens    tests    iib    maximum    medication    days    injectable    clinical    alleviates    school    immunotherapy    popularity    histamine    launch    temporarily    tolerated    date    symptomatic   

Project "AllergyVAX" data sheet

The following table provides information about the project.

Coordinator
DESENTUM OY 

Organization address
address: RUNEBERGINKATU 49 A 22 LEXWELL OY
city: HELSINKI
postcode: 260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 3˙684˙750 €
 EC max contribution 1˙885˙000 € (51%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DESENTUM OY FI (HELSINKI) coordinator 1˙885˙000.00

Map

 Project objective

Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden. In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year. Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms. The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the immune system to tolerate allergens. However, typical AIT takes 3-5 years, involves monthly injections or daily drops/tablets and has the risk of serious allergic reactions during treatment. Thus, the popularity of AIT is still relatively low compared to symptomatic drugs. We have developed a platform technology for creating modified hypoallergens to be used in AIT. It is based on making small, highly targeted modifications to allergen proteins that reduce their ability to trigger allergic reactions during treatment without compromising their efficacy in building tolerance to natural allergens. With these modified hypoallergens, we expect to shorten the injectable AIT treatment from dozens of injections over 3 years to just 3-6 injections over a few months. From the clinically important major birch pollen allergen Bet v 1 we have created rBet v 1 dm hypoallergen. In preclinical tests it has shown 100-fold reduction in histamine release compared to natural allergens and induced similar immunological responses in mice that are desired in human AIT. In the AllergyVAX project we will test rBet v 1 dm for maximum tolerated dose and immunogenicity in allergic patients in a phase I/IIa clinical trial. The project will facilitate seamless transition to phase IIb-III clinical development, establishing a basis for product launch with selected partners and advancing other hypoallergens in the pipeline, including product candidates for grass pollen, dog, horse and peanut allergies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALLERGYVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALLERGYVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More